Transaction DateRecipientSharesTypePriceValue
21st December 2020Geoffrey Michael Glass18,600Bona fide gift$0.00
18th September 2020Thomas S Mchugh4,000Open or private purchase$6.00$24,000.00
17th September 2020Mark Anthony Mc Camish52,398Open or private purchase$5.83$305,249.79
17th September 2020Eric J Ende17,000Open or private purchase$5.79$98,375.60
16th September 2020Mark Anthony Mc Camish118,602Open or private purchase$5.73$679,968.99
28th August 2020Geoffrey Michael Glass4,800Open or private purchase$6.78$32,559.84
28th August 2020Thomas S Mchugh7,500Open or private purchase$6.77$50,776.50
14th August 2020Linda Palczuk2,500Open or private purchase$7.94$19,849.75
13th August 2020Eric J Ende3,800Open or private purchase$7.80$29,640.00
13th August 2020Eric J Ende1,200Open or private purchase$7.74$9,288.00
Avadel Pharmaceuticals Plc
Avadel Pharmaceuticals Plc logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 5/10.

Avadel Pharmaceuticals Plc engages in the development and commercialization of pharmaceutical products. The company offers Bloxiverz, Vazculep, and Akovaz.

Ticker: AVDL
Sector: Health Technology
Industry: Medical Specialties
SEC Central Index Key (CIK): 1012477
Employees: 50
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Cash at Carrying Value: $102 M (945%)
Marketable Securities, Current: $136 M (150%)
Other Assets, Current: $294 Th (174%)
Assets, Current: $277 M (236%)
Property, Plant and Equipment, Net: $407 Th (-25%)
Other Assets, Noncurrent: $38 M (0%)
Assets: $341 M (125%)
Accounts Payable, Current: $5 M (-20%)
Accrued Liabilities, Current: $16 M (0%)
Liabilities, Current: $27 M (-24%)
Long-term Debt, Excluding Current Maturities: $125 M (0%)
Other Liabilities, Noncurrent: $5 M (0%)
Liabilities: $159 M (-11%)
Common Stock, Value, Issued: $635 Th (48%)
Common Stock, Shares, Issued: $64 M (48%)
Additional Paid in Capital, Common Stock: $615 M (41%)
Retained Earnings (Accumulated Deficit): $361 M (-7%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $23 M (-1%)
Treasury Stock, Value: $500 Th (0%)
Treasury Stock, Shares: $54 M (0%)
Stockholders' Equity (Parent): $182 M (0%)
Liabilities and Equity: $341 M (125%)
Revenue: $10 M (0%)
Cost of Revenue: $3 M (-42%)
Research and Development: $4 M (-57%)
Restructuring Charges: $24 Th (-86%)
Operating Income/Loss: $40 M (19%)
Income before taxes: $36 M (40%)
Provision for income taxes: $5 M (25%)
EPS (basic): $0.57 (0%)
EPS (diluted): $0.49 (0%)